Welcome to our dedicated page for Cosciens Biopharma news (Ticker: CSCIF), a resource for investors and traders seeking the latest updates and insights on Cosciens Biopharma stock.
COSCIENS Biopharma Inc. reports developments for a life science company focused on natural, plant-based active ingredients, with additional disclosures covering pharmaceutical therapies, diagnostic products, and related corporate actions. Company news includes operating and financial results, restructuring and cost-management updates, strategic decisions affecting subsidiaries, and commercialization matters for Macrilen, an oral diagnostic test for adult growth hormone deficiency.
Recurring updates also cover public-company status matters, including the company’s voluntary Nasdaq delisting, plans involving U.S. reporting obligations, shareholder meeting materials, capital-structure proposals, and responses to market activity in its common shares.
COSCIENS Biopharma (OTCQB: CSCIF) reported Q1 2026 net income of $10.8 million, or $3.42 per share, versus a $3.7 million loss in Q1 2025, driven mainly by $10.9 million income from discontinued German operations.
Revenue rose to $1.9 million and operating expenses fell to $1.5 million, reducing the net loss from continuing operations to $0.2 million. The company deconsolidated its insolvent German subsidiaries, plans a share reorganization to suspend SEC reporting, and decided not to advance the AvenActive program.
COSCIENS Biopharma (OTCQB: CSCIF) filed a Rule 13e-3 Transaction Statement with the SEC on April 20, 2026 proposing a two-step Share Capital Amendment to reduce U.S. holders of record below 300 and seek suspension of Exchange Act reporting.
The plan consolidates 150 pre-consolidation shares into one, then splits 50-for-1; holders under 150 would receive US$1.60 per pre-consolidation share and be cashed out. The company estimates approximately US$1.9 million in annualized cost savings if SEC Reporting Suspension is allowed. Shareholder approval at the June 2026 meeting is planned.
COSCIENS Biopharma (OTCQB: CSCIF; TSX: CSCI) issued a notice on April 7, 2026 responding to recent unusual market activity. The company said it does not normally comment on market speculation and confirmed it is not aware of any material undisclosed information that would explain the recent trading increase.
COSCIENS Biopharma (OTCQB: CSCIF, TSX: CSCI) reported Q4 and full‑year 2025 results and a corporate update on March 25, 2026. The company ended 2025 with $7.3M cash, Q4 net loss of $2.2M and FY net loss of $10.4M. Revenue for FY 2025 was $7.5M. Management ceased funding its German subsidiaries and filed for insolvency there on March 23, 2026, expecting ~$1.9M annualized cost savings and removal of €11.0M pension liabilities from consolidation. The company plans to propose suspending Exchange Act reporting while remaining a Canadian reporting issuer and listed on the TSX and OTC market.
COSCIENS (FINRA: CSCIF, TSX: CSCI) announced it will cease funding its German subsidiaries Aeterna Zentaris GmbH and Zentaris IVF GmbH, prompting an expected structured insolvency process and anticipated surrender of rights to Macrilen® (macimorelin). The company cited disappointing Phase 3 DETECT results and a Type C FDA meeting as a setback to pediatric expansion plans.
The company said it will significantly reduce operating expenses and refocus on its active ingredients business, while evaluating other strategic options including sales, licenses, and U.S. entry alternatives.
COSCIENS (TSX: CSCI; FINRA: CSCIF) announced that subsidiary Aeterna Zentaris GmbH signed an exclusive 10-year distribution agreement with Wuzhou Drug International for Macrilen (macimorelin) in Hong Kong, Macao, Singapore, and Guangdong and Hainan provinces.
The deal assigns Wuzhou responsibility for registration, importation and commercialization and leverages the "Hong Kong and Macao Medicine and Equipment Connect" policy for expedited access in the Greater Bay Area. The agreement includes a minimum initial order of approximately €800,000.